الفهرس 
Introduction & Aim of workOnly 14 pages are availabe for public view
 |  | from | 205 |  |  |
| | | from | 205 | | |
Abstract
Liver fibrosis is a serious universal health problem that has been extensively reported and continues to place a burden on the public health system internationally. It is associated with substantial increase in the risk of morbidity and mortality from chronic health condition as inflammation, cholestasis, viral and genetic disorders. Liver cirrhosis is a dangerous factor leading to mortality as it predisposes to hepatic failure and primary liver cancer .
Endocannabinoids are a group of lipid-related molecules involved in many physiological functions, inflammatory responses and cell proliferation. They act primarily on two different types of cannabinoid receptors (CB1 and CB2). Previous studies showed that CB1 receptors mediate profibrogenic effects in liver and implicated in the pathogenesis of alcoholic and non-alcoholic liver disease. However, activation of CB2 receptors inhibits or even reverses liver fibrogenesis, in non-hepatic tissue and protects against liver injury.
Thereforethe present work aimedmainly to :
1-Clarify the contribution of cannabinoid receptors expression, inflammation, oxidative stress and apoptosis in liver fibrosis progression induced through bile duct ligation in rats.
2-Investigate the effects of treatment of BDL fibrotic rats with CB1 antagonist, hemopressin, curcumin or CB2 agonist β-caryophyllene ,and their combinations in comparison with silymarin, a well known hepatoprotective agent.
3-Study the effects of treatment with β-caryophyllene either alone or in combination with AM 630, CB2 antagonist, to find out whether its effect was mediated solely via CB2 activation or by other mechanisms.4-Find out the molecular mechanisms and new strategy implicated for treatment of liver fibrosis.
5-Investigate the possible correlation between the studied biochemical changes and the histological abnormalities in the liver of rats under study.